Skip to main content

Edesa Biotech, Inc.

EDSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001540159

No open-market purchases or sales by Edesa Biotech, Inc. insiders were filed in the last 90 days; 33 institutions reported holding it in 13F filings for Q2 2026, worth $30.0M in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding Edesa Biotech, Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025All holders in Q3 2025

13F holders of EDSA: Q3 2025 compared with Q4 2025
MeasureQ3 2025Of which not filed for Q4 2025Q4 2025Change
Holders231220
Shares2.88M13.05M+176.0K (+6.1%)
Value$7.10M$2$4.34M−$2.76M (−38.9%)

1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Edesa Biotech, Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to EDSA in Q4 2025
InstitutionSharesValue% of portfolio
DRW Securities, LLC134,222$190.6K0.01%
Diadema Partners LP54,025$76.7K0.05%
State Street Corp18,679$27.1K0.00%
Persistent Asset Partners Ltd12,319$17.5K0.01%
Morgan Stanley2,300$3.27K0.00%
Banque Cantonale Vaudoise3$00.00%

Sold out (6)

Institutions that held Edesa Biotech, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of EDSA in Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
Commonwealth Equity Services, LLC37,548$93.0K
Renaissance Technologies LLC25,000$61.8K
Susquehanna International Group, LLP14,610$35.6K
Citigroup Inc2,000$4.88K
Fifth Third Bancorp100$247
Barclays PLC6$14

Not filed for Q4 2025 yet (1)

Institutions that held Edesa Biotech, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding EDSA in Q3 2025 that haven't filed for Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
AllSquare Wealth Management LLC1$2